Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland

•ALL is associated with considerable clinical and economic burden.•Median OS was 28.9 months, 76 % of patients were hospitalized (mean 1.1 time/month).•MRD+ patients have worse prognosis than MRD- patients.•Median OS for MRD+ patients was 15.3 months; MRD-: not reached.•Efforts should be made to adhere to recommendations for MRD testing in clinical guidelines.